RIVM launches study on long-term effectiveness of COVID-19 vaccines RIVM is launching an extensive study today to research the long-term effectiveness of the various COVID-19 vaccines in the Netherlands.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.